SciSparc Ltd (SPRC): רווח נקי למניה ב-12 החודשים האחרונים

SciSparc Ltd (SPRC) brings together neurobiologists, offering them academic freedom and stock options to study the central nervous system. The pharmacology team is developing unique therapies for rare pathologies. The 12-month net income per share trend clearly demonstrates patterns where -79.40 serves as the base parameter value. However, the costs of cannabinoid clinical trials are depleting reserves, forcing management to aggressively cut operating expenses.

Real earnings dynamics are critical for assessing the investment attractiveness of SciSparc Ltd (SPRC). Analyzing the trailing 12-month net income per share reveals the company's total income distributed per share. This metric filters out speculative noise, demonstrating the fundamental efficiency of the business. Amid the development of psychopharmacological drugs and partnerships for the treatment of Tourette syndrome, this indicator confirms the startup's financial stability. Growth in this metric directly enhances the asset's M&A attractiveness.